

Anti-Multi-Drug Resistance Marker (P-Glycoprotein) [MDR88]

Catalog No.	Description
AM391-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AM391-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive™ Detection Systems and i6000™ Automated Staining Systems
MU391-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
MU391-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive™ Detection Systems OR equivalent detection system
AX391-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 160 tests
AX391-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 50 tests

Clone	Species	Ig Class
MDR88	Mouse	IgG1, Kappa

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of Multi-drug resistance marker in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

Multi-drug resistance marker (P-glycoprotein) is a 170 kD cell membrane protein of the multidrug resistance gene, MDR-1. Studies have linked the presence of P-glycoprotein with resistance to a wide variety of chemotherapeutic agents. P-glycoprotein is associated with an efflux pump that actively removes drug from the cell, thereby conferring resistance to a variety of drugs. P-glycoprotein is also found in various concentrations in most normal tissues, suggesting that the primary role for this protein is in normal secretion of physiological metabolites. Elevated levels of P-glycoprotein in tumor cell lines have been correlated with multi-drug resistance. In normal human tissues the highest levels of P-glycoprotein expression were localized in the kidney, adrenal glands, liver, and intestine. In a series of human tumors not selected for drug resistance, P-glycoprotein was most commonly associated with colon, renal, and adrenal carcinomas. It was rarely detected in lung and gastric carcinomas and was not detected in breast and endometrial

carcinomas. Studies have shown that weakly resistant cancer cells established in tissue culture showed cytoplasmic immunoreactivity for P-glycoprotein, whereas in highly drug resistant cell lines, plasma membrane immunoreactivity was observed.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The [primary antibody](#) may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody Multi-drug resistance marker is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations
Control Tissue	ADRENAL GLAND tissue as available with Biogenex FB-391M* & FG-391M*
Recommended Dilution for Concentrated Antibody	1:20-50 in HK156
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)
Recommended Pretreatment (Xmatrx)	EZ-AR2 Elegance (HX032-YCD)
Antibody Incubation	30-60 Min at RT

Category	Antibodies	Revision No.	K
Document No.	932-391M-EN	Release Date	May 31, 2021

(Manual/i6000)	
Antibody Incubation (Xmatrx)	30-60 Min at RT
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive™ Polymer-HRP IHC Detection System/DAB; see p. 2 for more information

*FB: positive control barrier slides, FG: positive control non-barrier slides. Xmatrx requires barrier slides.

**Pretreatment times will vary based on individual microwave power.

***For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit
Manual	QD440-XAKE (1000 Test)	QD630-XAKE (1000 Test)	QP300-XAKE (1000 Test)
	QD430-XAKE (1000 Test)		
	QD420-YIKE (500 Test)	QD620-XAKE (500 Test)	QP900-9LE (500 Test)
	QD400-60KE (60 Test)		
Xmatrx - Automation	QD550-YCDE (200 Test)	QD610-YADE (200 Test)	N/A
i6000 - Automation	QD410-YAXE (200 Test)	QD610-YAXE (200 Test)	N/A
For more information, visit www.biogenex.com .			

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149

or support@biogenex.com or your local distributor to report unusual staining.

Expected Results







This antibody stains membrane & cytoplasm in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- Kartner, N., et al. Nature 316:820-823, 1985.
- Cordon-Cardo, C., et al. J Histochem Cytochem 38:1277-1287, 1990.
- Scheper, R.J., et al. Int J Cancer 42:389-394, 1988.
- Chan HSL, et al. Lab Invest 59:870-875, 1988.
- Hamada H, et al. Cell Biol 83:7785-7789, 1986

	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
	Use By Date	LOT	Batch Code
	Non-Sterile		Consult Instructions for Use
	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	K
Document No.	932-391M-EN	Release Date	May 31, 2021